Excellence in clinical trials has long been a strength of the retina community. Retinal physicians around the world have collaborated on studies ranging from first-in-human trials to large phase 3 clinical trials, bringing cutting-edge treatments to patients. In this July/August issue of Retinal Physician, Dr. Jeremiah Brown and colleagues discuss the important topic of inclusion in clinical research. They delve into misconceptions that contribute to underrepresentation of certain populations in research. Then, they discuss opportunities to increase inclusion of populations that would help trials reflect real-world patient demographics.
Retina surgeons also encounter complex surgical cases each day. Dr. James Rice and colleagues share their expertise for removing intraocular foreign bodies from the posterior segment. They review surgical tips for various surgical approaches including direct sclerotomy extraction to delivery via an inferior port. Continuing the topic of surgery, for this issue Dr. Christina Weng leads a surgical panel discussion that includes Dr. John Miller, Dr. Raymond Iezzi, and Dr. Suzie Gasparian, in which the surgeons review and discuss the management of 4 complex surgical cases. The videos and discussion are available on the Retinal Physician website. Drs. Luis Acabá-Berrocal and Maria Berrocal review the surgical evidence for using scleral buckling in phakic rhegmatogenous retinal detachment. They delve into the peer-reviewed literature to evaluate visual acuity outcomes and anatomic success comparing scleral buckling to primary pars plana vitrectomy. In addition, they discuss technical refinements that improve outcomes and decrease the risk of surgical complications. In addition, Ms. Elizabeth Cifers reviews proper retina surgery coding, discussing the importance of thorough documentation, coding rules, and understanding the bundling of surgical procedures.
How often do you manage and treat patients with uveitis? Many of us refer patients with posterior uveitis and have used both local and systemic medications to control the vision-threatening inflammation. In this issue Dr. Sruthi Arepalli reviews the latest updates on local steroids for uveitis and outlines upcoming changes that may affect the armamentarium.
On behalf of the editorial board, I want to express our gratitude for your support. During the busy summer, I hope you have time to rest and recharge. We appreciate your taking the time to read Retinal Physician—thank you for your partnership. RP
